Updated August 6, 2026.
Health Canada has not approved retatrutide, and Canadian pharmacies do not sell it commercially. It remains an investigational once-weekly medicine developed by Eli Lilly under the research code LY3437943. Phase 2 data and 2026 Phase 3 topline results have made retatrutide weight loss a major topic, but Canadians cannot currently obtain it as a Health Canada-authorized prescription drug. Lilly says no regulatory agency has approved retatrutide and plans its first U.S. regulatory submission in the first quarter of 2027.
Retatrutide Canada: quick answer
- Health Canada approval: No.
- Canadian pharmacy availability: No authorized retail product.
- What it is: An investigational GIP, GLP-1 and glucagon receptor agonist.
- Latest results: Phase 3 topline data were announced in 2026; full peer-reviewed reporting is still developing.
- Legitimate access: Only through an eligible clinical trial—not through an ordinary prescription.
- Canadian COA example: View the Red Leaf Peptides Janoshik report or visit the Peptide Factory Canada Retatrutide research product page.
This article is educational, not medical advice. Research-use products are not approved medicines and are not for human or veterinary use.
What is retatrutide?
Retatrutide is an experimental peptide-based medicine designed to activate three metabolic hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon. This is why researchers call it a triple agonist, triple hormone receptor agonist or GIP/GLP-1/glucagon agonist.
However, the glucagon receptor differentiates retatrutide from semaglutide, a single GLP-1 receptor agonist, and tirzepatide, a dual GIP/GLP-1 receptor agonist. Researchers are studying whether this three-pathway mechanism can produce greater effects on appetite, body weight, glucose regulation and energy metabolism. For a deeper scientific overview, read our retatrutide guide and key facts or our primer on what peptides are and how peptide safety is evaluated.
| Term | Meaning |
|---|---|
| Retatrutide | Investigational once-weekly triple receptor agonist |
| LY3437943 | Lilly’s research code for retatrutide |
| GIP | Glucose-dependent insulinotropic polypeptide |
| GLP-1 | Glucagon-like peptide-1 |
| Glucagon | A hormone pathway involved in glucose and energy regulation |
| TRIUMPH | The Phase 3 retatrutide obesity trial program |
Is retatrutide approved in Canada?
No. Health Canada has not approved retatrutide as of August 6, 2026. It therefore has no Canadian Drug Identification Number (DIN), approved product monograph, authorized brand name or standard pharmacy supply. Health Canada’s Drug Product Database is the official place to verify drugs authorized for sale in Canada.
Lilly also states that no regulatory agency has approved retatrutide. Its July 2026 update said the company plans to submit a U.S. Biologics License Application in Q1 2027. A U.S. filing is not a Canadian approval, and a future Canadian authorization would require Health Canada’s own review of quality, safety and efficacy. There is no reliable public retatrutide approval date for Canada.
Is retatrutide available in Canada?
Retatrutide is not available as a routine Canadian prescription. A doctor cannot prescribe a Health Canada-approved retatrutide product because one does not yet exist. Some Canadian sites participated in retatrutide clinical studies, but enrolment depends on a protocol’s location, status and eligibility criteria.
For example, searches such as retatrutide Canada pharmacy, retatrutide prescription Canada, retatrutide for sale Canada and buy retatrutide online Canada can surface products that are not authorized medicines. A label such as “research use only” does not turn a compound into a drug for self-treatment.
Retatrutide results: what Phase 2 and Phase 3 found
The best-known peer-reviewed evidence is the 2023 Phase 2 obesity trial published in The New England Journal of Medicine. Among 338 adults, the estimated mean body-weight change at 48 weeks reached -24.2% in the 12 mg study group versus -2.1% with placebo. Gastrointestinal events were the most common adverse events, and heart-rate increases were dose-dependent.
In May 2026, Lilly announced topline TRIUMPH-1 Phase 3 results. Adults with obesity or overweight and at least one weight-related condition, without diabetes, lost an average of up to 28.3% at 80 weeks in the 12 mg group under the efficacy estimand. Lilly later reported positive topline results from TRIUMPH-2 and TRIUMPH-3. These sponsor-announced results are important, but readers should distinguish a news release from a complete peer-reviewed publication and regulatory review.
| Study | Population | Reported result | Evidence status |
|---|---|---|---|
| Phase 2 obesity trial | 338 adults with obesity or overweight plus a weight-related condition | Up to 24.2% mean weight reduction at 48 weeks | Peer-reviewed |
| TRIUMPH-1 | Obesity or overweight with a comorbidity, without diabetes | Up to 28.3% average reduction at 80 weeks | 2026 sponsor topline report |
| TRIUMPH-2 | Obesity or overweight with type 2 diabetes | Up to 20.8% average reduction at 80 weeks | 2026 sponsor topline report |
| TRIUMPH-3 | Severe obesity with cardiovascular disease, with or without diabetes | Up to 22.6% average reduction at 80 weeks | 2026 sponsor topline report |
Important context: study averages are not personal predictions. Results depend on the protocol, analysis method, dose assignment, treatment adherence, participant characteristics and duration. Clinical trials also include medical supervision that an unregulated online product cannot reproduce.
How does retatrutide work?
Retatrutide’s proposed mechanism combines three signals:
- GLP-1 receptor activity is associated with appetite regulation, delayed gastric emptying and glucose-dependent insulin effects.
- GIP receptor activity contributes to glucose-dependent insulin secretion and metabolic signalling.
- Glucagon receptor activity may affect hepatic glucose output, fat oxidation and energy expenditure.
The goal of a triple agonist is not simply to “stack three weight-loss drugs.” It is to engineer one molecule with a balanced receptor profile. Whether its benefits outweigh its risks for specific conditions is a question for large trials and regulators.
Retatrutide side effects and safety
The most frequently reported retatrutide side effects have been gastrointestinal. In clinical studies these included nausea, diarrhea, vomiting, constipation and reduced appetite. Phase 2 also observed dose-related increases in heart rate that peaked around week 24 and later declined.
In addition, potential safety questions for the broader incretin class can include gallbladder disease, pancreatitis, dehydration-related kidney problems, hypoglycemia when combined with certain diabetes drugs, and loss of lean mass during rapid weight reduction. Final retatrutide contraindications, boxed warnings, drug interactions and monitoring requirements cannot be known until regulators evaluate the complete data and an approved product monograph exists.
Safety warning: Do not inject, ingest or self-dose a product marketed as research retatrutide. Lilly warns that illicit products claiming to be retatrutide may contain unknown ingredients, contaminants, the wrong ingredient, or too much or too little active substance.
Retatrutide dosage: what the studies mean—and do not mean
Search interest in retatrutide dosage, retatrutide dose, retatrutide dosing schedule and retatrutide titration is high. Clinical trials evaluated assigned once-weekly doses and gradual escalation under a controlled protocol. Those research doses are not instructions for personal use.
However, there is currently no Health Canada-approved retatrutide dose, prescribing information or titration schedule. Individual trial protocols use eligibility screening, randomization, study visits, adverse-event reporting and medical monitoring. Converting a trial arm into a do-it-yourself plan ignores product identity, sterility, medical history and safety oversight.
Retatrutide vs Ozempic, Wegovy and Mounjaro
Retatrutide is investigational; semaglutide and tirzepatide are established medicines with approved uses that vary by product and jurisdiction. Ozempic and Wegovy contain semaglutide. Mounjaro contains tirzepatide. They are not interchangeable with retatrutide, and comparisons across separate trials cannot prove that one drug is superior.
| Compound | Receptor targets | Canadian context |
|---|---|---|
| Retatrutide (LY3437943) | GIP + GLP-1 + glucagon | Investigational; not Health Canada approved |
| Tirzepatide (Mounjaro) | GIP + GLP-1 | Approved product; indication and coverage depend on current Canadian labelling and plan rules |
| Semaglutide (Ozempic, Wegovy) | GLP-1 | Approved products with different labelled indications |
When people search retatrutide vs Ozempic, retatrutide vs Wegovy, retatrutide vs Mounjaro, retatrutide vs tirzepatide or retatrutide vs semaglutide, the first comparison should be regulatory status—not a headline percentage. Approved medicines have standardized manufacturing, official labels, pharmacy controls and post-market safety reporting.
Retatrutide clinical trials in Canada
For example, Canada has hosted sites in the TRIUMPH and TRANSCEND programs. For example, the U.S. National Library of Medicine’s TRIUMPH-Outcomes record lists Canadian research locations and describes a cardiovascular and kidney outcomes study. The TRIUMPH-1 record shows that study as completed and no longer recruiting.
To search for an open retatrutide clinical trial in Canada:
- Search ClinicalTrials.gov for “retatrutide” or “LY3437943.”
- Filter by Canada and recruiting status.
- Read the eligibility criteria, contacts and locations on the official record.
- Discuss participation with your physician and contact the listed study team—not a third-party seller.
However, a listed Canadian site does not guarantee open enrolment. Never pay an online vendor for supposed “clinical trial access.”
Retatrutide price in Canada and insurance coverage
There is no official retatrutide price in Canada. Because there is no authorized product, there is no manufacturer list price, standard pharmacy price, provincial formulary listing or approved private-insurance benefit to compare.
Therefore, advertisements that quote a retatrutide Canada price are not pricing a Health Canada-approved retatrutide medicine. Future cost, insurance coverage, prior authorization and public reimbursement would be determined only after regulatory and commercial decisions.
Can you buy retatrutide online in Canada?
You cannot currently buy an approved retatrutide medicine online in Canada. For example, an online listing may describe a chemical sold for laboratory research, but it is not an authorized therapeutic product and should not be used in people or animals. Packaging, a vial size, an analytical certificate or the words “pharmaceutical grade” do not create Health Canada approval.
Therefore, researchers evaluating legitimate laboratory materials should separate analytical procurement from clinical use and review documentation such as identity testing, purity methodology, batch traceability and a certificate of analysis. Qualified laboratories can also review the Retatrutide research product page for current vial formats, research-use restrictions and available documentation. Our educational guide to research peptides and scientific interest explains that distinction, while our Canadian peptide sourcing guide covers research-focused verification questions. These resources do not provide human dosing or treatment advice.
Retatrutide COA example from a Canadian provider
For example, a useful retatrutide COA Canada example is the October 2025 third-party Janoshik Analytical report supplied by Red Leaf Peptides. The report identifies Retatrutide, manufacturer RLF, batch RLF-00001, and task number #84327. It reports 10.66 mg measured content and 99.059% purity, with analysis completed October 22, 2025.
Janoshik Analytical Retatrutide COA for task #84327 and batch RLF-00001. The tested sample reported 10.66 mg content and 99.059% purity. Click the image to open the complete three-page report.
View the batch documentation
- View Retatrutide product information for qualified laboratory research
- Open the complete Retatrutide Janoshik COA (PDF)
- Visit the Red Leaf Peptides Retatrutide research page
Red Leaf Peptides is a Canada-focused research-peptide provider that publishes third-party batch documentation. Its Janoshik report supplies a task number, batch identifier, measured content and purity result that researchers can review instead of relying only on a marketing purity claim.
Important: This report applies only to the tested sample and batch. A COA does not establish Health Canada approval, clinical safety, sterility, efficacy or suitability for human or veterinary use.
How to read a retatrutide certificate of analysis
For example, when reviewing a retatrutide certificate of analysis, confirm the laboratory name, client, manufacturer, batch number, sample identity, measured content, purity result, analysis date and verification key. The batch on the vial or procurement record should match the batch shown on the report. Researchers should also distinguish identity and purity testing from sterility, endotoxin and heavy-metal testing because one result does not automatically cover every quality attribute.
Retatrutide approval timeline for Canada
Therefore, the most accurate answer is that no confirmed Canadian launch date exists. The likely path would include completion and analysis of pivotal trials, a company submission, Health Canada review, a regulatory decision, manufacturing and distribution planning, and then separate reimbursement decisions.
- Clinical development: Phase 3 studies generate efficacy and safety evidence.
- Regulatory submission: The sponsor submits a full dossier to a regulator.
- Health Canada review: Regulators assess quality, safety and efficacy.
- Decision and monograph: Approval would establish authorized indications, warnings and dosing.
- Market access: Supply, pricing and public or private coverage follow separate processes.
However, Lilly’s planned 2027 U.S. submission does not establish a Health Canada filing date. Check official databases rather than social-media countdowns or reseller claims.
Frequently asked questions about retatrutide Canada
1. Is retatrutide approved in Canada?
No. As of August 6, 2026, retatrutide is not approved by Health Canada and has no Canadian DIN or approved product monograph.
2. Is retatrutide available in Canada?
Not as an authorized prescription or retail pharmacy product. Eligible participants may encounter retatrutide only within a legitimate clinical study.
3. What is retatrutide?
Retatrutide, also called LY3437943, is an investigational once-weekly GIP, GLP-1 and glucagon receptor agonist developed by Eli Lilly.
4. Is retatrutide a GLP-1 drug?
It includes GLP-1 receptor activity, but researchers more precisely describe it as a triple agonist because it also targets GIP and glucagon receptors.
5. What were the retatrutide weight-loss results?
A peer-reviewed Phase 2 study reported up to 24.2% mean weight reduction at 48 weeks. Lilly’s 2026 TRIUMPH-1 topline report announced up to 28.3% average reduction at 80 weeks under its efficacy analysis. These are group averages, not guaranteed individual outcomes.
6. Are the 2026 retatrutide Phase 3 results peer-reviewed?
Some detailed data have been presented publicly, but major 2026 figures were initially announced as sponsor topline results. Full peer-reviewed publications and regulatory review provide a more complete assessment.
7. What are the common retatrutide side effects?
Clinical studies most commonly reported gastrointestinal effects such as nausea, diarrhea, vomiting, constipation and reduced appetite. Phase 2 also found dose-related increases in heart rate.
8. Is retatrutide safe?
Regulators are still evaluating its benefit-risk profile. Trial monitoring cannot establish that unapproved or illicit products are safe, pure or correctly labelled.
9. What is the approved retatrutide dosage?
There is no approved retatrutide dosage in Canada. Trial doses and titration schedules are research protocols, not self-use instructions.
10. How much will retatrutide cost in Canada?
No official Canadian price exists because retatrutide is not approved or marketed. Future price and coverage cannot yet be confirmed.
11. Will Canadian insurance cover retatrutide?
There is no standard coverage for an unapproved retail product. Any future provincial or private coverage would follow approval, pricing and formulary decisions.
12. Can a Canadian doctor prescribe retatrutide?
Not as a Health Canada-approved retatrutide medicine. Clinical-trial investigators may administer it only under an authorized study protocol.
13. Are there retatrutide clinical trials in Canada?
Yes, Canadian locations have participated in retatrutide studies. Recruiting status changes, so verify current records and contacts on ClinicalTrials.gov.
14. Can I buy retatrutide online in Canada?
You cannot buy a Health Canada-approved retatrutide medicine because none exists. Online “research” listings are not authorized for human or veterinary use.
15. Is research retatrutide the same as prescription retatrutide?
No. A research chemical is not an approved medicine and is not supported by an authorized product monograph, pharmacy dispensing controls or established clinical-use standards.
16. Is compounded retatrutide available in Canada?
Claims about compounded retatrutide require extreme caution because no approved reference product or authorized retatrutide monograph exists. Do not assume a compounded or custom-labelled vial matches clinical-trial material.
17. What is the difference between retatrutide and Ozempic?
Retatrutide targets GIP, GLP-1 and glucagon receptors and remains investigational. Ozempic contains semaglutide, targets GLP-1 and is an approved medicine for its labelled indication.
18. What is the difference between retatrutide and Mounjaro?
Retatrutide is a triple GIP/GLP-1/glucagon agonist. Mounjaro contains tirzepatide, a dual GIP/GLP-1 agonist with established regulatory labelling.
19. Does retatrutide treat type 2 diabetes?
Researchers are studying retatrutide in people with type 2 diabetes, including the Phase 3 TRIUMPH-2 and TRANSCEND programs, but it is not approved in Canada to treat diabetes.
20. When will retatrutide be approved in Canada?
No company or regulator has announced a confirmed date. Lilly plans its first U.S. filing in Q1 2027, but Canada requires a separate Health Canada submission and review.
Bottom line
For anyone searching retatrutide Canada, the central fact is simple: the compound has promising obesity and metabolic research results, including 2026 Phase 3 topline data, but it remains investigational and unavailable as a Health Canada-approved prescription. Watch official regulatory databases and clinical-trial registries, distinguish peer-reviewed evidence from company announcements, and do not treat research-use material as medicine.
Sources and further reading
